Melissa Bitsura
Family · Coraopolis, PANPI 1629808944
Payments from drug & device makers
Across 258 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$595
- Ardelyx, Inc.$378
- Regeneron Healthcare Solutions, Inc.$292
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$291
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,05598%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,211 |
| Johnson & Johnson | 58 | $1,099 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $595 |
| Ardelyx, Inc. | 15 | $378 |
| Regeneron Healthcare Solutions, Inc. | 10 | $292 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $291 |
| Pfizer | 16 | $243 |
| Ipsen Biopharmaceuticals, Inc | 8 | $210 |
| Celltrion USA Inc. | 8 | $173 |
| Madrigal Pharmaceuticals | 11 | $141 |
| Daiichi Sankyo Inc. | 5 | $122 |
| Organon | 6 | $102 |
| Lilly USA, LLC | 5 | $78 |
| Evoke Pharma, Inc. | 4 | $59 |
| Sanofi | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Intercept Pharmaceuticals, Inc. | 1 | $27 |
| Biocon Biologics Inc | 1 | $26 |
| Merck | 1 | $24 |
| Novo Nordisk | 1 | $21 |
How this compares
$5,174 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 24 | $1,641 |
| Ondansetron OdtOndansetron | 20 | $69 |
Paid to pharmacies, not to this prescriber.
Other family in Coraopolis
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.